{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".006","upperLimit":"13","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"The rate of failure to mobilize will be estimated by dividing the number of patients that fail to mobilize by the total number of evaluable patients. A patient is considered a failure if they never achieve 2.5 million CD34 cells/kg.","dispersionType":"95% Confidence Interval","groups":[{"description":"Plerixafor 160mg/kg/dose by IV on days 5-8\n\nFilgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.","id":"OG000","title":"Plerixafor"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Duration of apheresis (up to 7 days)","title":"Rate of Failure to Mobilize","type":"SECONDARY","unitOfMeasure":"percentage of participants"}